The $1bn valuation round was led by Symbotic to support the development of fast-charging power solutions for autonomous systems.
"Nyobolt is enabling the always-on, always-moving infrastructure that physical AI demands. The enterprises deploying autonomous systems at scale can’t afford downtime, swap time, or power flickers. Our technology delivers a powerful trifecta: improved performance, exceptional durability, and a more sustainable operation, enabling a new generation of machines to run harder and smarter."
— Sai Shivareddy, Co-founder and Chief Executive Officer
The Series A round was led by YFM Equity Partners with participation from Mercia Ventures.
"Our mission has always been to bring transparency to the student accommodation market – both for the students and for the sector. On the student side, we want every student to be able to choose where they study and live with confidence, powered by authentic, verified reviews from people with real experience. On the industry side, we have built a dataset that gives operators, investors and advisers the independent, accurate data they need to make optimal decisions. This funding enables us to invest in the platform to better support decision-making for the students and the sector. While researching mainland Europe and the US, we discovered similar challenges and are working with launch partners to expand the platform into these geographies. In the UK, we are further innovating the platform to enhance data-driven decision-making."
The oversubscribed round was led by DSW Ventures with backing from Scottish Enterprise, SWIM Capital and the University of Strathclyde.
"We’re excited to enter the next stage for Northern Light Microscopy. With the technology validated, this funding enables us to move forward into initial sales, scaling and product line expansion."
The seed round was co-led by LocalGlobe and Breega.
"We are enabling the creation of more perfect crystals in orbit that unlock drug formulations simply not achievable on Earth–a paradigm shift for cancer therapies and the pharmaceutical industry at large"